CA
NZ
UK
AU
IND
US
● It means the FDA cannot approve the application in its current form.
● Revenue was $384,000 a year earlier.
● Rivian moved with the EV sector, which took its cue from Tesla.
● Revenue was $267.8 million, ahead of the $258 million expected.
● The reason for the removal was not given.
● AdjustedEarningsof $4.43 a share crushed the $3.27 consensus.
● A rival offer of $28 per share had emerged.
● It was grouped with Entegris and Monolithic Power among soaring chip stocks.
● It compares with a $110.4 million loss a year earlier.
● The stock traded at $142.07 on the ticker bar.
Please wait processing your request...